B-Cell Leukemia

This is a type of leukemia that starts in the B-cells, which are a type of white blood cell. It's a common type of leukemia.

Condition

What people with B-Cell Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for B-Cell Leukemia?

NameHow it went

About B-Cell Leukemia

What It Is

B-cell leukemia is a cancer of B lymphocytes (B cells), the white blood cells that normally make antibodies to fight infection. Abnormal B cells multiply in the bone marrow and blood. They do not fight infection well, and as they build up they crowd out the healthy cells the marrow should be making. That is why the main effects are frequent infections, anemia (too few red blood cells, which causes tiredness and shortness of breath) and easy bruising or bleeding. B-cell leukemia is an umbrella term rather than a single disease, and its main forms behave very differently. Chronic lymphocytic leukemia (CLL), the most common form, usually grows slowly. It mostly affects older adults and is often found on a routine blood test before it causes any symptoms. B-cell acute lymphoblastic leukemia (ALL) starts in very early, immature B cells and gets worse quickly if it is not treated. It is the most common cancer in children, but it also affects adults. Rarer forms include hairy cell leukemia, which is slow-growing and often enlarges the spleen, and B-cell prolymphocytic leukemia, which progresses faster than typical CLL. Knowing the exact type is the first step, because it decides the outlook and the treatment.

Causes & Risk Factors

Leukemia starts when the genetic material (DNA) in a developing blood cell changes in a way that lets it grow out of control. These changes are usually acquired during life rather than inherited, and in most people no specific cause is found. Risk factors differ by type. For CLL, the strongest is age: most people are diagnosed after 50, and the median age at diagnosis in the United States is 71. A family history of CLL or other blood and bone marrow diseases raises the risk, CLL is more common in white people, and exposure to certain chemicals, including the herbicide Agent Orange used in the Vietnam War, has been linked to it. For ALL, risk factors include earlier chemotherapy or radiation therapy, exposure to high levels of radiation, and certain genetic conditions such as Down syndrome. Having a risk factor does not mean someone will develop leukemia, and many people who do have no known risk factor.

How It's Diagnosed

Diagnosis usually begins with a complete blood count (CBC) with differential, a blood test that counts red blood cells, platelets and each kind of white blood cell. A very high lymphocyte count, or low red cell or platelet counts, can point toward leukemia. CLL is often discovered this way in someone who feels well. Flow cytometry, a lab test that reads the markers on the surface of cells, confirms that the abnormal cells are B cells and identifies which type of leukemia it is. For ALL and hairy cell leukemia, a bone marrow aspiration and biopsy (a sample of marrow and bone taken with a needle, usually from the hip) is a standard part of the workup. Genetic tests on the leukemia cells matter because they guide treatment. In CLL, changes in genes such as TP53 help predict how the disease will behave and which drugs are likely to work. In ALL, testing looks for the Philadelphia chromosome, a swap between chromosomes 9 and 22 that calls for an added targeted drug. Most people with hairy cell leukemia have a change in the BRAF gene. In ALL, a lumbar puncture (spinal tap) checks the fluid around the brain and spinal cord, since leukemia cells can spread there. CLL is staged from 0 to IV. Stage 0 means only a high lymphocyte count; higher stages add enlarged lymph nodes, liver or spleen, and then low red blood cell or platelet counts. ALL has no stages. Instead, it is described as untreated, in remission (normal blood counts and 5% or fewer immature leukemia cells, called blasts, in the marrow) or recurrent.

Treatment Options

Treatment depends on the type, so the options for CLL and ALL look very different. For CLL that causes no symptoms, the usual approach is watchful waiting: regular checkups and blood tests, with treatment starting when symptoms appear or blood counts change. When treatment is needed, the main options are targeted medicines. BTK inhibitors (BTK stands for Bruton tyrosine kinase), including ibrutinib (Imbruvica), acalabrutinib (Calquence) and zanubrutinib (Brukinsa), are pills that block a signal CLL cells depend on to survive and grow. Venetoclax (Venclexta) is a pill that blocks BCL2, a protein that keeps CLL cells alive, and is usually combined with an antibody infusion such as obinutuzumab or rituximab. These approaches have not all been compared directly, so the choice rests on genetic test results, age, other health conditions and which side effects matter most. BTK inhibitors raise the risk of bleeding, especially alongside blood thinners, and can cause heart rhythm problems. Venetoclax is started at a low dose and increased gradually, with blood tests and extra fluids, because killing many leukemia cells at once can cause tumor lysis syndrome, a flood of cell contents into the blood that can damage the kidneys. Chemotherapy with rituximab remains an option for some people. B-cell ALL is treated promptly and intensively. The first phase, induction, aims to clear leukemia from the blood and marrow and bring a remission. Later phases destroy remaining cells that could cause a relapse. Because standard chemotherapy does not reach the brain and spinal cord well, treatment to protect them, often chemotherapy injected into the spinal fluid, is given along the way. People with Philadelphia chromosome-positive ALL also take a tyrosine kinase inhibitor such as imatinib or dasatinib. Immunotherapies aimed at markers on B cells have widened the options: blinatumomab (Blincyto) links a person's own T cells to the leukemia cells, inotuzumab ozogamicin is an antibody that delivers a cell-killing drug, and CAR T-cell therapy (CAR stands for chimeric antigen receptor) re-engineers a person's T cells to attack the leukemia. These are used in particular when leukemia remains after treatment or comes back. They can trigger a strong body-wide immune reaction or nervous system side effects, so care teams watch closely for both. A stem cell transplant is an option for some people at high risk of relapse. Hairy cell leukemia that causes no problems may simply be watched. When treatment is needed, the chemotherapy drugs cladribine or pentostatin often bring a long-lasting remission. Clinical trials are open for every type and can be considered at diagnosis or at relapse.

What to Expect

Daily life with CLL often involves long stretches of monitoring rather than active treatment, and many people live with it for years. Over time, blood counts, lymph node size and symptoms guide when treatment starts or changes. Targeted pills are taken at home, and some are continued for long periods, so routine blood tests and checks for side effects become part of life. Because CLL weakens the immune system, infections are a recurring concern, and the care team may check antibody levels. Less often, CLL changes into a faster-growing lymphoma or prolymphocytic leukemia, which needs a new plan. B-cell ALL treatment is demanding at first, with frequent hospital visits or stays and close attention to infection, followed by a longer and less intensive phase to keep the leukemia away. Children do especially well: about 98% reach remission, and more than 90% of children and teenagers treated on current regimens are alive five years later. Outcomes in adults are less favorable and depend heavily on age, genetic findings such as the Philadelphia chromosome, and how quickly the leukemia responds. Survivors, especially those treated as children, need long-term follow-up for late effects such as heart, bone or fertility problems, changes in learning or memory, and second cancers. Hairy cell leukemia usually responds well. When it returns after a remission, treating it again often brings another remission. Follow-up continues for years, partly to watch for second cancers.

When to Seek Help

Arrange a medical visit if you have ongoing tiredness, painless swollen lymph nodes in the neck, armpit or groin, easy bruising, tiny red spots under the skin, a feeling of fullness below the ribs, or infections that keep coming back. These have many causes, but a simple blood count can show whether leukemia is a possibility. If you have CLL and are being monitored, tell your care team about drenching night sweats, unexplained weight loss, ongoing fevers or lymph nodes that are growing quickly, since these can mean the disease is changing. During treatment, contact your care team right away, day or night, for a fever of 100.5°F (38°C) or higher, chills or other signs of infection. Infections during leukemia treatment can be life-threatening and need urgent attention.

Questions to Ask Your Doctor

  1. 1.Which type of B-cell leukemia do I have, and what do the genetic test results say about how it is likely to behave?
  2. 2.Does it need treatment now, or is monitoring the right choice, and what changes would make us start treatment?
  3. 3.What are the realistic goals of the treatment you recommend, and how do its side effects compare with the alternatives?
  4. 4.How can I lower my risk of infection, and exactly when should I call you about a fever?
  5. 5.Would a clinical trial, CAR T-cell therapy or a stem cell transplant evaluation make sense for me?

Last reviewed • Oct 2026

Educational content, not medical advice.